PCSK9 pipeline shows signs of saturation
Astrazeneca and Ionis’s discontinuation could herald a nervous time for others in this space.
Problems Facing The Current Generation Of Genetic Medicines
A new report from Evaluate Vantage looks at new approaches aiming to solve problems facing the current generation of genetic medicines.
Intellia’s in vivo Crispr stays in play, clinically at least
Though broad questions intensify, NTLA-2001 continues showing clinically what it is meant to.
Biotech listings shows few signs of cooling
IPOs of drug developers raised $9bn in the first half of 2021, a record amount that is hard to square with talk of moderation.
Intellia proves its point
The first clinical evidence for in vivo gene editing, and a surge in valuation, is to be celebrated. But there is much more to do.
